Celcuity Inc. (CELC)
NASDAQ: CELCHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 65.50 -0.43%
CELC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.22B
- EPS (TTM)
- -$4.17
- Dividend yield
- None
- 52-week range
- 45.03 – 151.02
- Day range
- 64.16 – 73.51
- Volume / Avg
- 2.62M / 1.19M
- Beta
- —
- Shares outstanding
- 48.93M
52-week range
CELC stock today
Shares of Celcuity (CELC) finished lower on Oct 7 at $65.78, a drop of 7.68% or $5.47 per share, versus the S&P 500's 0.22% decline. Volume was 2.2x the average at 2.62M shares, a sign of unusually heavy trading. Shares are 56.4% below their 52-week high of $151.02, set on May 4, 2026 and 46.1% above the 52-week low of $45.03, near the bottom of the past year's range.
CELC is down 34.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 33.4%. Celcuity has posted a net loss over the last twelve months (EPS of -$4.17), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Celcuity
Company profileCelcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Brian F. Sullivan
- Headquarters
- Minneapolis, MN
- Employees
- 155
- IPO year
- 2017
- Website
- celcuity.com
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$156.91+138.54%
- Strong buy 3
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Celcuity peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs CELC |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs CELC |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs CELC |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs CELC |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs CELC |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs CELC |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs CELC |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs CELC |
Indexes, lists and sector
Appears in lists
Celcuity stock FAQ
What is Celcuity's stock price today?
CELC last traded at $65.78 as of Oct 7, 4:00 PM EDT, down 7.68% on the day. Prices are delayed at least 15 minutes.
Who is Celcuity's CEO?
Mr. Brian F. Sullivan is the chief executive officer of Celcuity Inc., which has about 155 employees.
What is the CELC 52-week high?
The 52-week high for CELC is $151.02 and the 52-week low is $45.03. The stock is currently 56.4% below its high.